Proactive Investors - Run By Investors For Investors

BioDiem delivers more positive results for eye disease drug

BioDiem delivers more positive results for eye disease drug

BioDiem (ASX: BDM) has strengthened the preclinical case for its BDM-E eye disease drug with further positive results from formal studies that will help progress out-licensing opportunities for the drug.

BDM-E has received Orphan Drug designation from the United States Food and Drug Administration for the treatment of the inherited degenerative eye disorder, retinitis pigmentosa.

The results, which were presented at the International Society for Eye Research meeting in Berlin recently, confirm the potential of BDM-E to reduce formation of abnormal blood vessel growth; reduce the signs of damage typical to retinitis pigmentosa; and improve the function of the retina and inhibit the death of cells imperative for sight.

BioDiem recently signed a research agreement with the Foundation Fighting Blindness, a leading U.S. eye research advocate, to test BDM-E in a pre-clinical model of retinitis pigmentosa, a genetic cause of blindness without effective treatment options.

Extensive portfolio

BioDiem has an extensive technology portfolio targeting multiple infectious diseases and cancers, supported by existing licence income with strong growth, as well as existing licences to the World Health Organization, Serum Institute of India and Changchun BCHT Biotech Co, China.

Its strong pipeline of products with high value disease targets include the large market influenza, schistosomiasis, hepatitis and tuberculosis; and the high value niche market fungal diseases, Methicillin-resistant Staphylococcus aureus (MRSA), sexually transmitted diseases, and viral-related cancers.

BioDiem’s core technologies include the Live Attenuated Influenza Virus (LAIV), the SAVINE platform and the BDM-I antimicrobial compound.

The company is also developing BDM-E, a tetra peptide synthetic compound, as a treatment for ophthalmic disorders.

BioDiem already has an influenza vaccine on the market.

Proactive Investors is a market leader in the investment news space, providing ASX “Small and Mid-cap” company news, research reports, StockTube videos and One2One Investor Forums.

View full profile View Profile


September 25 2012

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use